Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B/gastrin receptor antagonists: Generation of predictive model

Journal of Chemical Information and Modeling

Volumn 45, Issue 6, 2005, Pages 1934-1942

  Chopra, Madhu ^a   Mishra, Anil K ^b  

^a UNIVERSITY OF DELHI   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; CYTOLOGY; FEATURE EXTRACTION; HYDROPHOBICITY; MATHEMATICAL MODELS;

LIGANDS; MOLECULAR MODELING;

MOLECULAR DYNAMICS;

CHOLECYSTOKININ B RECEPTOR; LIGAND;

ALGORITHM; ARTICLE; ARTIFICIAL INTELLIGENCE; CHEMICAL STRUCTURE; DRUG ANTAGONISM; FACTUAL DATABASE; PREDICTION AND FORECASTING; REPRODUCIBILITY;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; DATABASES, FACTUAL; LIGANDS; MODELS, MOLECULAR; PREDICTIVE VALUE OF TESTS; RECEPTOR, CHOLECYSTOKININ B; REPRODUCIBILITY OF RESULTS;

EID: 28944438983     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci050257m     Document Type: Conference Paper

References (68)

1. Walsh, J. H. Gastrin. In Gut Peptides; Walsh, J. H., Dockray, G. J., Eds.; Raven Press: New York. 1994; pp 75-121.
2. Johnson, L. R. Trophic Effects of Gut Peptides. In Handbook of Physiology; Makhlouf, G. M., Ed.; American Physiological Society: Bethesda, MD, 1989; Section 6, pp 291-310.
3. Johnson, L. R. The Trophic Action of Gastrointestinal Hormones. Gastroenterology 1976, 70, 278-288.
4. Hakanson, R.; Sundler, F. Tropic Effects of Gastrin. Scand. J. Gastroenterology 1991, 70 (Suppl. 180), 130-136.
5. Kopin, A. S.; Lee, Y.; McBride, E. W.; Miller, L. J.; Lu, M.; Lin, H. Y.; Kolakowski, L. F.; Beinborn, M. Expression, Cloning and Characterization of the Canine Parietal Cell Gastrin Receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3605-3609.
6. Wank, S. A.; Pisegna, J. R.; de Weerth, A. Brain and Gastrointestinal Cholecystokinin Receptor Family: Structure And Functional Expression. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8691-8695.
7. Mantyh, C. R.; Pappas, T. N.; Vigna, S. R. Localization of the Cholecystokinin A and Cholecystokinin B/Gastrin Receptors in the Canine Upper Gastrointestinal Tract. Gastroenterology 1994, 107, 1019-1030.
8. Nakamura, M.; Oda, M.; Kaneko, K.; Akaiwa, Y.; Tsukada, N.; Komatsu, H.; Tsuchiya, M. Autoradiographic Demonstration of Gastrin-Releasing Peptide-Binding Sites in the Rat Gastric Mucosa. Gastroenerology 1988, 94, 968-976.
9. Schjoldager, B.; Molero, X.; Miller, L. J. Functional and Biochemical Characterization of the Human Gall Bladder Muscularis Cholecystokinin Receptor. Gastoenterology 1989, 96, 1119-1125.
10. Sandvik, A. K.; Waldum, H. L. CCK-B (Gastrin) Receptor Regulates Gastric Histamine Release and Acid Secretion. Am. J. Physiol. 1991, 260, G925-G928.
11. Walsh, J. H. Role of Gastrin as a Trophic Hormone. Digestion 1990, 47, 11-16.
12. Reubi, J. C. Neuropeptide Receptors in Health and Disease: The Molecular Basis for In Vivo Imaging. J. Nucl. Med. 1995, 3, 1825-35.
13. Krenning, E. P.; Kwekkeboon, D. J.; Pauwels, S. Somatostatin Receptor Scintigraphy. Nucl. Med. Ann. 1995, 1-50.
14. Otte, A.; Mullar- Brand, J.; Dellas, S. Yttrium-90-Labeled Somatostatin- Analogue for Cancer Treatment. Lancet 1998, 351, 417-18.
15. Reubi, J. C.; Waser, B. Cholecystokinin (CCK-A) and CCK-B/Gastrin Receptors in Human Tumors. Cancer Res. 1997, 57, 1377-86.
16. Behr, T. M.; Jenner, N.; Behe, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled Peptide for Targeting Cholecystokinin-B/Gastrin Receptor-Expressing Tumors. J. Nucl. Med. 1999, 40, 1029-1044.
17. Trivedi, B. K. Ligands for Cholecystokinin Receptors: Recent Developments. Curr. Opin. Ther. Pat. 1994, 4 (1), 31-44.
18. Trivedi, B. K. Cholecystokinin Receptor Antagonists: Current Status. Curr. Med. Chem. 1994, 1, 313-327.
19. Blommaert, A. G. S.; Weng, J.-H.; Dorville, A.; McCort, I.; Ducos, B.; Durieux, C.; Roques, B. P. Cholecystokinin Peptidomimetics as Selective CCK-B Antagonists: Design, Synthesis, and in Vitro and in Vivo Biochemical Properties. J. Med. Chem. 1993, 36, 2868-2877.
20. Trivedi, B. K.; Padia, J. K.; Holmes, A.; Rose, S.; Wright, D. S.; Hinton, J. P.; Pritchard, M. C.; Eden, J. M.; Kneen, C.; Webdale, L.; Suman-Chauhan, N.; Boden, P.; Singh, L.; Field, M. J.; Hill, D. Second Generation "Peptoid" CCK-B Receptor Antagonists: Identification and Development of N-(Adamantyloxycarbonyl)-α-methyl-(R)-tryptophan Derivative (CI-1015) with an Improved Pharmacokinetic Profile J. Med. Chem. 1998, 41, 38-45.
21. Lipinski, C. A. Drug-like Properties and the Causes of Poor Solubility and Poor Permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
23. Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000.
24. Martin, Y. C. Pharmacophore mapping. In Designing Bioactive Molecules: Three-Dimensional Techniques and Application; Martin, Y. C., Willett, P., Eds.; American Chemical Society: Washington, DC, 1998; pp 121-148.
25. Clark, D. E.; Westhead, D. R.; Sykes, R. A.; Murray, C. W. Activesite-Directed 3D Database Searching: Pharmacophore Extraction and Validation of hits. J. Comput.-Aided Mol. Des. 1996, 10, 397-416.
26. Doweyko, A. M. Three-dimensional Pharmacophores from Binding Data. J. Med. Chem. 1994, 37, 1769-1778.
27. Mason, J. S.; Good, A. C.; Martin, E. J. 3-D Pharmacophores in Drug Discovery. Curr. Pharm. Des. 2001, 7, 567-597.
28. Milne, G. W.; Nicklaus, M. C.; Wang, S. Pharmacophores in Drug Design and Discovery. SAR QSAR Environ. Res. 1998, 9, 23-38.
29. PhRMA: New Medicines in Development Series, 2001 (http://www.phrma.org/ publications/documents/factsheets/2001-03-01.210.phtml).
30. Catalyst, version 4.7; Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego, CA, 2000.
31. Greenidge, P. A.; Weiser, J. A Comparison of Methods for Pharmacophore Generation with the Catalyst Software and their use for 3D-QSAR: Application to a set of 4-Aminopyridine Thrombin Inhibitors. Mini-Rev. Med. Chem. 2001, 1, 79-87.
32. Palomer, A.; Pascual, J.: Cabre, F.; Garcia, M. L.; Mauleon, D. Derivation of Pharmacophore and CoMFA Models for Leukotriene D(4) Receptor antagonists of the quinolinyl(bridged)aryl series. J. Med. Chem. 2000, 43, 392-400.
33. Duffy, J. C.; Deardon, J. C.; Green, D. S. V. Use of Catalyst in the Design of Novel Non-Steroidal Anti-inflammatory Analgesic Drugs. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sana, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, Spain, 1995; pp 289-291.
34. Huffman, R. D.; Bourguignon, J. J. Building a Hypothesis for CCK-B Antagonists Using Catalyst Program. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, Spain, 1995; pp 298-300.
35. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
36. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Eds.; ESCOM Science Publishers B. V.: Leiden, The Netherlands, 1995; pp 1-21.
37. Quintana, J.; Contijoch, M.; Cuberes, R.; Frigola, J. Structure Reactivity Relationships and Molecular Modeling Studies of a Series of H1 Antihistamines. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, Spain, 1995; pp 282-288.
38. Barbaro, R.: Betti, L.; Botta, M.; Corelli, F.; Giannaccini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Corsano, S. Synthesis, Biological Evaluation, and Pharmacophore Generation of New Pyridazinone Derivatives with Affinity toward R1- and R2-Adrenoceptors. J. Med. Chem. 2001, 44, 2118-2132.
39. Baringhaus, K. H.; Matter, H.; Stengelin, S.; Kramer, W. Substrate Specificity of the Heal and the Hepatic Na(+)/Bile Acid Cotransporters of the Rabbit. II. A Reliable 3D QSAR Pharmacophore Model for the Heal Na( + )/Bile Acid Cotransporter. J. Lipid Res. 1999, 40, 2158-2168.
40. Ekins, S.; de Groot, M. J.: Jones, J. P. Pharmacophore and Three-Dimensional Quantitative Structure Activity Relationship Methods for Modeling Cytochrome P450 Active Sites. Drug Metab. Dispos. 2001, 29, 936-944.
41. Hirashima, A.; Rafaeli, A.; Gileadi, C.; Kuwano, E. Three-Dimensional Pharmacophore Hypotheses of Octopamine Receptor Responsible for the Inhibition of Sex-Pheromone Production in Helicoverpa Armigera. J. Mol. Graphics Model. 1999, 17, 43-44.
42. Karki, R. G.; Kulkarni, V. M. A Feature Based Pharmacophore for Candida Albicans MyristoylCoA: Protein N-Myristoyltransferase Inhibitors. Eur. J. Med. Chem. 2001, 36, 147-163.
43. Manetti, F.; Corelli, F.; Biava, M.; Fioravanti, R.; Porretta, G. C.; Botta, M. Building a Pharmacophore Model for a Novel Class of Antitubercular Compounds. Farmaco 2000, 55, 484-491.
44. Ekins, S.; Bravi, G.; Ring, B. J.; Gillespie, T. A.; Gillespie, J. S.; Vandenbranden, M.; Wrighton, S. A.; Wikel, J. H. Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6. J. Pharmacol. Exp. Ther. 1999, 288, 21-29.
45. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three- and Four-Dimensional Quantitative Structure Activity Relationship Analyses of Cytochrome P-450 3A4 Inhibitors. J. Pharmacol, Exp. Ther. 1999, 290, 429-438.
46. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three and four dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2D6 Inhibitors. Pharmacogenetics 1999, 9, 477-489.
47. Grigorov, M.; Weber, J.; Tronchet, J. M.; Jefford, C. W.; Milhous, W. K.; Maric, D. A QSAR Study of the Antimalarial Activity of Some Synthetic 1,2,4-Trioxanes. J. Chem. Inf. Comput. Sci. 1997, 37, 124-130.
48. Lopez-Rodriguez, M. L.; Porras, E.; Benhamu, B.; Ramos, J. A.; Morcillo, M. J.; Lavandera, J. L. First Pharmacophoric Hypothesis for 5-HT7 Antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
49. Daveu, C.; Bureau, R.; Baglin, I.; Prunier, H.; Lancelot, J. C.; Rault, S. Definition of a Pharmacophore for Partial Agonists of Serotonin 5-HT3 Receptors. J. Chem. Inf. Comput. Sci. 1999, 39, 362-369.
50. Norinder, U. Refinement of Catalyst Hypotheses Using Simplex Optimisation. J. Comput.-Aided Mol. Des. 2000, 14, 545-557.
51. Bureau, R.; Daveu, C.; Baglin, I.; Sopkova-De Oliveira, S. J.; Lancelot, J. C.; Rault, S. Association of two 3D QSAR Analyses. Application to the Study of Partial Agonist Serotonin-3 Ligands. J. Chem. Inf. Comput. Sci. 2001, 41, 815-823.
52. Kurogi, Y.; Güner, O. F. Pharmacophore Modeling and Three-Dimensional Database Searching for Drug Design Using Catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
53. Güner, O. F.; Waldman, M.; Hoffman, R.; Kim, J.-H. Strategies for Database Mining and Pharmacophore Development. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Eds.; International University Line: La Jolla, CA, 2000; pp 213-236.
54. Langer, T.; Hoffman, R. D.; Bachmair, F.; Begle, S. Chemical Function Based Pharmacophore Models as Suitable Filters for 3D Database Searching. THEOCHEM 2000, 500, 59-72.
55. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsutsumi, K.; Nasu, M.; Moriyasu, M. Discovery of Novel Mesangial Cell Proliferation Inhibitors using a Three-Dimensional Database Searching Method. J. Med. Chem. 2001, 44, 2304-2307.
56. Briens, F.; Bureau, R.; Rault, S. Applicability of CATALYST in Ecotoxicology, a New Promising Tool for 3D-QSAR: Study of Chlorophenols. Ecotoxicol. Environ. Saf. 1999, 43, 241-251.
57. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
58. Semple, G.; Ryder, H.; Rooker, D. P.; Batt, A. R.; Kendrick, D. A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishida, A.; Akuzawa, S.; Miyata, K. (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1, 4-benzodiazepin-3-yl)-N-(3-(methylamino)phenyl)urea (YF476); A Potent and Orally Active Gastrin/CCK-B Antagonist. J. Med. Chem. 1997, 40, 331-341.
59. Kalindjian, S. B.; Buck, I. M.; Davies, J. M. R.; Dunstone, D. J.; Hudson, M. L.; Low, C. M. R.; McDonald, I. M.; Pether, M. J.; Steel, K. I. M.; Tozer, M. J.; Vinter, J. G.; Non-Peptide Cholecystokinin-B/Gastrin Receptor Antagonists Based on Bicyclic. Heteroaromatic Skeletons. J. Med. Chem. 1996, 39, 1806-1815.
60. Blommaert, A. G. S.; Weng, J.-H.; Dorville, A.; McCort, I.: Ducos. B.; Durieux, C.; Roques, B. P. Cholecystokinin Peptidomimetics as Selective CCK-B Antagonists: Design, Synthesis, and in Vitro and in Vivo Biochemical Properties. J Med. Chem, 1993, 36, 2868-2877.
61. Yu, M. J.; Thrasher, K. J.; McCowan, J. R.; Mason, N. R.; Mendelsohn, L. G. Quinazolinone Cholecystokinin-B Receptor Ligands. J. Med. Chem. 1991, 34, 1505-1508.
62. Drysdale, M. J.; Pritchard, J. M. C.; Horwell, D. C. Rationally Designed "Dipeptoid" Analogues of CCK. Acid Mimics of the Potent and Selective Non-Peptide CCK-B Receptor Antagonist CI-988. J. Med. Chem. 1992, 55, 2573-2581.
63. Padia, J. K.; Field, M.; Hinton, J.; Meecham, K.; Pablo, J.; Pinnock, R.; Roth, B. D.; Singh, L.; Suman-Chauhan, N.; Trivedi, B. K.; Webdale, L. Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists. J. Med. Chem. 1998, 41, 1042-1049.
64. 2 Receptor Antagonists. J. Med. Chem. 2000, 43, 3518-3529.
65. Urisini, A.; Capelli, A. M.; Carr, R. A. E.; Cassara, P.; Corsi, M.; Curcuruto, O.; Curotto, G.; Cin, M. D.; Davali, S.; Donati, D.; Feriani, A. Finizia, G.; Gaviraghi, G.; Marien, M.; Pentassuglia, G.; Polinelli, S.; Ratti, E.; Reggiani, A.; Tarzia, G.; Tedesco, G.; Tranquillini, M. E.; Trist, D. G.; Van Amsterdam, F. T. M. Synthesis and SAR of New 5-phenyl-3-ureido-1,5- benzodiazepines as cholecystokinin-B Receptor Antagonists. J. Med. Chem. 2000, 43, 3596-3613.
66. Bock, M. G.; DiPardo, R. M.; Evans, B..E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine gastrin and brain Cholecystokinin receptor ligands; L-365, 260. J. Med. Chem. 1989, 32 (1), 13-16.
67. Evans, B. E.; Bock, M. G.; Rittle, K. E.; DiPardo, R. M.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Design of Potent, Orally Effective, Nonpeptidal Antagonists of the Peptide Hormone Cholecystokinin. PNAS 1986, 83 (13), 4918-4922.
68. Tromelin, A.; Guichard, E. Use of Catalyst in a 3D-QSAR Study of the Interactions between Flavor Compounds and β-Lactoglobulin. J. Agric. Food Chem. 2003, 51, 1977-1983.